Two real diagnostics, anonymized

We predicted what the room would say before the room said it. Here's the receipt.

Every ClarityInvest diagnostic is produced blind — before we've seen any feedback from the founder's real investor conversations. What follows are two anonymized cases, shown exactly as delivered, next to what the room actually said afterward.

3–4 / 5

Objections and kill signals independently confirmed by the room, typical across engagements

1–2 / 5

Missed or reprioritized once real feedback came in — tracked, not hidden

We're not claiming a guaranteed close rate — that's a different, harder claim, and one we're not going to fabricate. This is a claim about prediction accuracy, and it's the one we can actually show our work on.

Case 01 · Named-fund sprint

"Interesting AI company with early revenue — but the whole decision turns on whether the platform channel is real enough to produce low-CAC growth."

Anonymized Seed, $2M ask AI / data infrastructure Specific fund, named partners

The founder was three weeks from a call with a specialist fund's two decision-makers. Before that call happened, and before we'd heard a word of real feedback, we delivered the sentence above as our prediction of what the fund would carry into its investment committee — plus the six specific things most likely to stop the deal.

Compression map — what survives, mutates, or dies in the room

This is the mechanic, shown on five of the seventeen claims we mapped for this founder.

Dimension	Founder's claim	Room's version
Category	"We are creating a new causal AI category." Mutates	"Customer pull matters more than category originality at this stage." Vision discounted
Distribution	"We have integrations with major platforms." Mutates	"Integration is not distribution unless it creates customer access, usage, and revenue." Becomes the hinge
Revenue	"We have early booked revenue and a late-stage pipeline." Survives	"Good start, but the conversion path must be shown bottom-up." Evidence discounted forward
Use of funds	"The round converts pipeline and scales revenue across platforms." Mutates	"The target is clear. The mechanics need proof before the room can underwrite it." Turns into diligence pressure
Team	"10+ years of domain and product experience." Survives	"Enough credibility for a Seed look." Holds

What was most likely to stop this deal.

"No CAC" without contractual proof

Integration ≠ commercial distribution. The room would ask for revenue and customer access per platform, not just API access.

Revenue bridge without a bottoms-up model

The 18-month ARR target needed outlets, attach rate, ACV, and sales capacity shown explicitly — not asserted.

Cap table friction

A broad shareholder base and a note overhang needed a clean pro forma before the fund could lead comfortably.

What happened next: on the walkthrough call after the founder's real conversations, four of the six flagged signals were confirmed near word-for-word — including the exact "integration is not distribution" objection. One was reprioritized (the cap table mattered less than predicted); one hadn't surfaced yet at that stage of diligence.

Case 02 · Capital lane diagnostic

"Credible team and strong channel access — but the immediate question isn't which investor to pitch. It's which capital should fund the next proof state."

Anonymized Pre-seed, zero runway Health / diagnostics platform Multi-lane capital sequencing

This founder had been treating their raise as one €1.5m ask and getting rejected by generalist VCs. The diagnostic identified something different: the company actually had three separate financing needs — a small non-dilutive validation grant, a proof bridge, and the full seed — and was taking all three to the wrong market at once.

Correcting the founder's own read

The founder believed venture was "blocked." The evidence said otherwise.

The read changed: repeated VC rejections did not mean venture was closed. One fund had already progressed through multiple diligence calls, so venture was conditional — just not the best use of zero-runway founder time.

The move: split the €1.5m ask into a non-dilutive validation grant, a strategic/angel proof bridge, and the full seed after real-world validation.

Your pipeline probably has a version of one of these two leaks.

The intake takes two minutes and tells you honestly which one — or if ClarityInvest isn't the right tool for where you are.

Start the 2-minute intake

No commitment · Free routing call · Diagnostics from €2,500